Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

SMMT

Summit Therapeutics Inc

Dec 12 • 04:00PM ET

17.87

Dollar change -0.90
Percentage change -4.79	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN GILD NBIX ALNY BIIB AMGN SRPT AKTX PRTA

| Held by: VTI VB IWM VXF VBR XBI IWO SCHA IBB VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.28	Insider Own	85.96%	Shs Outstand	737.09M	Perf Week	2.00%
Market Cap	13.17B	Forward P/E	-	EPS next Y	-0.41	Insider Trans	0.00%	Shs Float	103.50M	Perf Month	-13.92%
Income	-196.71M	PEG	-	EPS next Q	-0.08	Inst Own	11.49%	Short Float	16.27%	Perf Quarter	-44.03%
Sales	0.00M	P/S	-	EPS this Y	70.62%	Inst Trans	17.23%	Short Ratio	4.20	Perf Half Y	120.89%
Book/sh	0.59	P/B	30.08	EPS next Y	-41.13%	ROA	-54.54%	Short Interest	16.84M	Perf Year	712.27%
Cash/sh	0.66	P/C	27.03	EPS next 5Y	-	ROE	-73.22%	52W Range	2.06 - 33.89	Perf YTD	584.67%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-44.49%	52W High	-47.27%	Beta	-0.91
Dividend TTM	-	Quick Ratio	8.31	Sales past 5Y	-28.65%	Gross Margin	-	52W Low	767.48%	ATR (14)	1.25
Dividend Ex-Date	-	Current Ratio	8.31	EPS Y/Y TTM	82.45%	Oper. Margin	-	RSI (14)	43.47	Volatility	6.59% 6.28%
Employees	105	Debt/Eq	0.07	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.33	Target Price	33.33
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	-153.77%	Payout	-	Rel Volume	0.40	Prev Close	18.77
Sales Surprise	-	EPS Surprise	25.15%	Sales Q/Q	-	Earnings	Oct 30 BMO	Avg Volume	4.01M	Price	17.87
SMA20	-3.86%	SMA50	-8.99%	SMA200	52.39%	Trades		Volume	1,622,050	Change	-4.79%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-11-24	Initiated	Wells Fargo	Overweight	$30
Dec-06-24	Initiated	Jefferies	Buy	$31
Nov-04-24	Initiated	JMP Securities	Mkt Outperform	$32
Sep-27-24	Downgrade	Citigroup	Buy → Neutral	$19 → $23
Aug-12-24	Initiated	H.C. Wainwright	Buy	$16
May-07-24	Initiated	Citigroup	Buy	$7
Mar-26-24	Initiated	Stifel	Buy	$8
Jun-28-18	Downgrade	Janney	Buy → Neutral
May-02-18	Initiated	Janney	Buy
Apr-12-18	Reiterated	Needham	Buy	$30 → $27
Feb-13-18	Initiated	BTIG Research	Buy	$33
Jan-04-18	Initiated	SunTrust	Buy	$24
Dec-01-17	Resumed	H.C. Wainwright	Buy	$16
Nov-16-16	Reiterated	RBC Capital Mkts	Outperform	$26 → $29
Oct-05-16	Reiterated	Needham	Buy	$22 → $30
Sep-16-16	Initiated	H.C. Wainwright	Buy	$26
Mar-30-15	Initiated	Oppenheimer	Outperform	$28
Mar-30-15	Initiated	Needham	Buy	$22

Show Previous Ratings

Dec-06-24 07:09PM	Why Summit Therapeutics Stock Rocketed 6% Higher on Friday (Motley Fool) +5.82%
Dec-02-24 04:22AM	Billionaire Ken Griffin Is Selling Palantir and Buying a Stock Wall Street Expects to Rocket 139% Higher (Motley Fool)
Nov-30-24 06:05AM	Warning: This Skyrocketing Stock Has a Hidden Risk (Motley Fool)
Nov-26-24 04:15PM	Summit Therapeutics to Present at Upcoming Investor Conferences (Business Wire)
Nov-23-24 06:30AM	3 Monster Stocks in the Making (Motley Fool)
04:15PM	Loading…
Nov-21-24 04:15PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-20-24 08:27AM	Summit Therapeutics (SMMT) Hurt Bronte Capital. Heres Why (Insider Monkey) -6.90%
Nov-14-24 04:54PM	Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics (Investor's Business Daily) -5.86%
Nov-10-24 06:26PM	TipRanks Perfect 10 Picks: 2 Top-Scoring Stocks for the Rest of 2024 (TipRanks)
Nov-08-24 07:00AM	2 Hot Biopharma Stocks to Buy and Hold for 5 Years (Motley Fool)
Nov-04-24 06:56PM	Why Summit Therapeutics Stock Was a Winner Today (Motley Fool) +5.11%
02:14PM	Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo (Benzinga)
01:43PM	Summit Therapeutics Leads the Parade of Big Gainers (GuruFocus.com)
Nov-03-24 06:41AM	3 Magnificent Stocks Under $100 to Buy in November (Motley Fool)
Oct-31-24 08:29AM	3 Stocks That Have Generated 1,000% Returns in Just 2 Years (Motley Fool)
07:01AM	Loading…
07:01AM	Summit Therapeutics Inc (SMMT) Q3 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
01:06AM	Decoding Summit Therapeutics Inc (SMMT): A Strategic SWOT Insight (GuruFocus.com)
Oct-30-24 07:00AM	Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024 (Business Wire) -14.57%
Oct-27-24 02:29PM	Is Summit Therapeutics a Millionaire Maker? (Motley Fool)
09:14AM	Summit Therapeutics Inc. (SMMT): An Unstoppable Stock That Could Make You Richer (Insider Monkey)
Oct-24-24 05:13AM	Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising? (Motley Fool)
Oct-23-24 04:15PM	Summit Therapeutics to Host Third Quarter 2024 Financial Results & Operational Progress Call on October 30, 2024 (Business Wire)
Oct-22-24 07:00AM	Billionaire Israel Englander Just Quietly Took a Stake in This Potentially Lucrative Pharmaceutical Stock. Should You? (Motley Fool)
Oct-20-24 02:23PM	Is Summit Therapeutics Inc. (SMMT) the Best QQQ Stock to Buy According to Analysts? (Insider Monkey)
Oct-15-24 06:30AM	Up 700% This Year, Is It Too Late to Invest in This Stock? (Motley Fool) +7.85%
Oct-13-24 12:11PM	Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit Therapeutics (Motley Fool)
Oct-12-24 09:15AM	3 Things You Need to Know If You Buy Summit Therapeutics Stock Today (Motley Fool)
Oct-09-24 05:04PM	Summit Therapeutics Inc (SMMT) Q2 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Oct-07-24 05:29AM	2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street Analysts (Motley Fool)
Oct-06-24 09:39AM	Summit Therapeutics Inc. (SMMT): Hedge Funds Are Bullish On This NASDAQ Stock Right Now (Insider Monkey)
11:12AM	Loading…
Oct-05-24 11:12AM	Is Summit Therapeutics a Millionaire Maker? (Motley Fool)
Oct-04-24 04:15PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
09:41AM	Summit Therapeutics Stock Jumps as Lung Cancer Drug Placed on FDA Fast Track (Investopedia)
07:45AM	Could Summit Therapeutics Become the Next Merck? (Motley Fool)
07:01AM	Is Summit Therapeutics Inc. (SMMT) the Best High Short Interest Stock to Invest In Now? (Insider Monkey)
04:32AM	Summit completes subject enrolment in Phase III NSCLC treatment trial (Clinical Trials Arena)
Oct-03-24 04:15PM	Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC (Business Wire)
09:00AM	Where Will Summit Therapeutics Be in 3 Years? (Motley Fool)
Oct-02-24 08:15AM	Has Summit Therapeutics Stock Already Peaked? (Motley Fool)
Sep-30-24 06:28AM	Is Summit Therapeutics Stock a Buy? (Motley Fool)
Sep-29-24 07:30AM	2 High-Potential Growth Stocks You Shouldn't Overlook (Motley Fool)
Sep-28-24 07:03AM	Better Rising Biotech: Viking Therapeutics vs. Summit Therapeutics (Motley Fool)
Sep-26-24 01:23AM	Is Summit Therapeutics Inc. (SMMT) the Best Performing Stock in 2024? (Insider Monkey)
Sep-25-24 04:56AM	2 Stocks Up Over 700% in 2024 That Could Soar Even Further (Motley Fool) -5.67%
Sep-23-24 07:00AM	How a Surfer Who Never Finished College Became a Biotech Billionaire (The Wall Street Journal) -10.17%
Sep-22-24 04:15PM	This Stock Is Crushing Nvidia's Performance This Year: Is It Too Late to Buy? (Motley Fool)
Sep-20-24 07:53AM	Keytruda beaten by Summits bispecific in NSCLC (Clinical Trials Arena) +5.31%
Sep-19-24 12:02PM	BioNTech Is More Than a Covid-19 Stock. Its Having a Great September. (Barrons.com) -5.70%
05:50AM	Is It Too Late to Buy Summit Therapeutics Stock After Its Almost 10X Gain This Year? (Motley Fool)
Sep-18-24 09:53AM	This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous. (Motley Fool) -6.33%
Sep-17-24 04:09PM	How BioNTech, Up 26% Over Four Days, Is Riding Summit's Coattails To A Recovery (Investor's Business Daily) -11.06%
04:24AM	Here's Why Everyone's Talking About Summit Therapeutics (Motley Fool)
Sep-16-24 06:30AM	Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024 (Business Wire) -7.67%
Sep-14-24 11:44AM	Is Summit Therapeutics Inc. (NASDAQ:SMMT) an Unstoppable Growth Stock To Buy Now? (Insider Monkey)
Sep-13-24 10:30AM	Why Summit Therapeutics Skyrocketed 123% This Week (Motley Fool) +16.49%
Sep-12-24 04:06PM	Summit Therapeutics, With 85% Gain This Week, Rockets Again On $235 Million Sale (Investor's Business Daily) +20.75%
11:53AM	Why Summit Therapeutics Stock Is Soaring Again Today (Motley Fool)
06:30AM	Summit Therapeutics Raises $235 Million (Business Wire)
Sep-11-24 07:08PM	Summit Therapeutics Co-CEOs on what's next for lung cancer drug (CNBC TV)
Sep-10-24 04:27AM	Is Summit Therapeutics a Buy Now? (Motley Fool) +20.01%
Sep-09-24 04:11PM	Merck Dives After Summit Up 56% Sneaks In With Keytruda-Walloping Punch (Investor's Business Daily) +55.99%
02:01PM	Why Summit Therapeutics Rocketed Over 60% Today (Motley Fool)
01:55PM	A Better Drug Than Mercks Blockbuster Keytruda? Not So Fast (The Wall Street Journal)
12:54PM	Top Stock Movers Now: Boeing, Palantir Technologies, Merck, and More (Investopedia)
12:13PM	Summits checkpoint inhibitor trumps Keytruda in lung cancer trial (Pharmaceutical Technology)
09:59AM	Merck stock falls on Summit cancer drug's trial results (Yahoo Finance Video)
09:54AM	Merck Stock Falls After Rival Summit Beats Keytruda Cancer Drug in Trial (Barrons.com)
09:50AM	Lung Cancer Drug Trial News Has Summit Therapeutics Stock Up 40% Today (Investopedia)
09:07AM	Merck Dives After Summit Therapeutics Sneaks In With Keytruda-Walloping Punch (Investor's Business Daily)
08:06AM	Biotech Stocks: Lung Cancer Treatment Outflanks Merck's Keytruda (Investor's Business Daily)
08:02AM	Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half (Benzinga)
Sep-08-24 11:45AM	Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China (Business Wire)
07:38AM	Summit lung cancer drug shows striking benefit over Keytruda (BioPharma Dive)
Sep-06-24 04:15PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +55.99%
Aug-12-24 07:00AM	HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at WCLC 2024 (Business Wire)
Aug-11-24 07:30PM	Two Ivonescimab (PD-1/VEGF) Results including Phase 3 Monotherapy versus Pembrolizumab Monotherapy in First-Line Treatment for PD-L1 Positive NSCLC to Be Presented at WCLC 2024 (PR Newswire)
Aug-09-24 04:15PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.27%
Aug-06-24 07:00AM	Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2024 (Business Wire)
Jul-29-24 04:15PM	Summit Therapeutics to Host Second Quarter 2024 Financial Results & Operational Progress Call on August 6, 2024 (Business Wire) -6.67%
Jul-25-24 08:00AM	Summit Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Development of Ivonescimab (Business Wire) +5.11%
Jul-03-24 04:15PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.62% +5.08%
Jun-27-24 04:15PM	Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors (Business Wire)
Jun-24-24 06:35AM	7 Top Stocks Under $10: June 2024 Edition (InvestorPlace)
Jun-17-24 05:50AM	3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street (Motley Fool) -5.84%
Jun-12-24 09:14AM	Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why (Zacks) +9.42%
Jun-03-24 05:30AM	Summit Raises $200 Million; Also Expands License Territories for Ivonescimab (Business Wire)
Jun-01-24 08:00AM	Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA (Business Wire)
May-31-24 07:00PM	Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy (Business Wire) -20.47%
12:21PM	Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study (Benzinga)
07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
04:25AM	Summit reports data from Phase III NSCLC treatment trial (Clinical Trials Arena)
May-30-24 06:00PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +272.06%
04:50PM	Summit Shares Soar After Cancer Drug Tops Mercks Keytruda (Bloomberg)
03:22PM	Competitor to Merck's Keytruda Worries Some Investors (Barrons.com)
02:29PM	Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China (Business Wire)
May-28-24 12:13PM	Why Summit Therapeutics Stock Is Sinking Today (Motley Fool) -29.29%
May-24-24 07:16AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) -21.76%
May-02-24 11:42AM	Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript (Insider Monkey) -13.62%
03:15AM	Summit Therapeutics Inc (SMMT) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ... (GuruFocus.com)
12:00AM	Q1 2024 Summit Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zanganeh Mahkam	Chief Executive Officer	Mar 27 '24	Buy	3.72	54,321	201,874	24,923,800	Mar 27 08:28 PM
Zanganeh Mahkam	Chief Executive Officer	Mar 26 '24	Buy	3.75	30,000	112,500	30,000	Mar 27 08:28 PM
Zanganeh Mahkam	Chief Executive Officer	Mar 27 '24	Buy	3.72	26,000	96,720	520,814	Mar 27 08:28 PM
Dhingra Ankur	Chief Financial Officer	Mar 26 '24	Buy	3.75	100,000	375,000	354,958	Mar 27 08:27 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SMMT

Summit Therapeutics Inc

Upgrade your FINVIZ experience